Literature DB >> 29878364

Repeat staging laparoscopy for gastric cancer after preoperative therapy.

Cornelius A Thiels1, Naruhiko Ikoma2, Keith Fournier2, Prajnan Das3, Mariela Blum4, Jeannelyn S Estrella5, Bruce D Minsky3, Jaffer Ajani4, Paul Mansfield2, Brian D Badgwell2.   

Abstract

BACKGROUND AND OBJECTIVES: Staging laparoscopy is recommended before preoperative therapy in patients with locoregional gastric cancer, but yield of repeated diagnostic laparoscopy at the time of resection is unknown.
METHODS: Retrospective review of a prospective database of patients with gastric adenocarcinoma (1994-2016) who had negative staging laparoscopy followed by preoperative therapy and subsequent attempted resection. Primary outcome was positive exploration (peritoneal or unresectable disease) at the time of resection. Multivariable logistic regression identified factors associated with positive exploration.
RESULTS: Of the 451 patients with attempted resection, 54 (12.0%) had positive explorations, including 48 with peritoneal disease. Patients with positive explorations were more likely to be female and have poorly differentiated tumors, linitis features, and signet-ring morphology. There was no significant difference by exploration results in age, race, clinical stage, or delayed definitive surgery. Positive explorations were independently associated with poor differentiation (OR 4.6, 95%CI 1.4-15.3; P = 0.01) and linitis (OR 4.2, 95%CI 1.9-9.2; P < 0.001). Positive explorations were seen in 14.0% of patients with poor differentiation, 36.6% of patients with linitis, and 5.8% of patients with neither linitis nor poor differentiation.
CONCLUSION: Despite negative pretreatment laparoscopy, post-treatment repeat laparoscopy may prevent non-therapeutic laparotomies. At a minimum, we recommend selective repeat laparoscopy for patients with linitis features.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  gastric cancer; laparoscopy; neoadjuvant; preoperative therapy; staging

Mesh:

Year:  2018        PMID: 29878364      PMCID: PMC7703853          DOI: 10.1002/jso.25094

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  30 in total

1.  Selection of patients with gastric adenocarcinoma for laparoscopic staging.

Authors:  Abeezar I Sarela; Robert Lefkowitz; Murray F Brennan; Martin S Karpeh
Journal:  Am J Surg       Date:  2006-01       Impact factor: 2.565

2.  Laparoscopic staging for gastric cancer.

Authors:  A M Lowy; P F Mansfield; S D Leach; J Ajani
Journal:  Surgery       Date:  1996-06       Impact factor: 3.982

Review 3.  Differences in the multimodal treatment of gastric cancer: East versus west.

Authors:  Ashley Russo; Ping Li; Vivian E Strong
Journal:  J Surg Oncol       Date:  2017-02-09       Impact factor: 3.454

4.  Minimally invasive gastrectomy for gastric adenocarcinoma in the United States: Utilization and short-term oncologic outcomes.

Authors:  Brett L Ecker; Jashodeep Datta; Matthew T McMillan; Sarah-Lucy C Poe; Jeffrey A Drebin; Douglas L Fraker; Daniel T Dempsey; Giorgos C Karakousis; Robert E Roses
Journal:  J Surg Oncol       Date:  2015-09-23       Impact factor: 3.454

5.  Video-laparoscopic staging of gastric cancer. A prospective multicenter comparison with noninvasive techniques.

Authors:  F Asencio; J Aguiló; J L Salvador; A Villar; E De la Morena; M Ahamad; J Escrig; J Puche; V Viciano; G Sanmiguel; J Ruiz
Journal:  Surg Endosc       Date:  1997-12       Impact factor: 4.584

6.  Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.

Authors:  J A Ajani; P F Mansfield; N Janjan; J Morris; P W Pisters; P M Lynch; B Feig; R Myerson; R Nivers; D S Cohen; L L Gunderson
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative.

Authors:  Linda X Jin; Dominic E Sanford; Malcolm Hart Squires; Lindsey E Moses; Yan Yan; George A Poultsides; Konstantinos I Votanopoulos; Sharon M Weber; Mark Bloomston; Timothy M Pawlik; William G Hawkins; David C Linehan; Carl Schmidt; David J Worhunsky; Alexandra W Acher; Kenneth Cardona; Clifford S Cho; David A Kooby; Edward A Levine; Emily Winslow; Neil Saunders; Gaya Spolverato; Graham A Colditz; Shishir K Maithel; Ryan C Fields
Journal:  Ann Surg Oncol       Date:  2016-03-22       Impact factor: 5.344

8.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 9.  Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy.

Authors:  Brian Badgwell; Prajnan Das; Jaffer Ajani
Journal:  J Hematol Oncol       Date:  2017-08-15       Impact factor: 17.388

Review 10.  The value of staging laparoscopy in gastric cancer.

Authors:  Nikolaos Machairas; Petros Charalampoudis; Ernesto P Molmenti; Stylianos Kykalos; Peter Tsaparas; Paraskevas Stamopoulos; Georgios C Sotiropoulos
Journal:  Ann Gastroenterol       Date:  2017-03-16
View more
  6 in total

Review 1.  [Complete response after neoadjuvant therapy for gastric cancer: implications for surgery].

Authors:  Giovanni Capovilla; Caterina Froiio; Hauke Lang; Felix Berlth; Peter Philipp Grimminger
Journal:  Chirurg       Date:  2021-10-07       Impact factor: 0.955

Review 2.  Anisi Stellati Fructus, a Significant Traditional Chinese Medicine (TCM) Herb and Its Bioactivity against Gastric Cancer.

Authors:  Maryam Khan; Saba Shamim
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

3.  The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.

Authors:  Qun Zhao; Changhong Lian; Zhibin Huo; Ming Li; Yang Liu; Liqiao Fan; Bibo Tan; Xuefeng Zhao; Zhidong Zhang; Dong Wang; Yu Liu; Honghai Guo; Peigang Yang; Yuan Tian; Yong Li
Journal:  Cancer Med       Date:  2020-06-24       Impact factor: 4.452

4.  Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.

Authors:  Jing Li; Qun Zhao; Xueke Ge; Yuzhi Song; Yuan Tian; Shuoshuo Wang; Ming Liu; Xueying Qiao
Journal:  BMC Surg       Date:  2021-03-17       Impact factor: 2.102

Review 5.  Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease.

Authors:  Hamza Khan; Fabian M Johnston
Journal:  J Surg Oncol       Date:  2022-06       Impact factor: 2.885

6.  Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Authors:  Yuan Tian; Qun Zhao; Yong Li; Liqiao Fan; Zhidong Zhang; Xuefeng Zhao; Bibo Tan; Dong Wang; Peigang Yang
Journal:  Gastroenterol Res Pract       Date:  2021-07-22       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.